ReWalk Robotics (NASDAQ:LFWD) Receives Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of ReWalk Robotics (NASDAQ:LFWD) in a report issued on Tuesday,Benzinga reports. They currently have a $13.00 target price on the stock.

Several other brokerages have also commented on LFWD. Laidlaw began coverage on ReWalk Robotics in a research note on Monday, February 10th. They set a “buy” rating and a $10.00 price target on the stock. Lake Street Capital dropped their target price on shares of ReWalk Robotics from $6.00 to $4.50 and set a “buy” rating on the stock in a report on Thursday, February 20th.

ReWalk Robotics Stock Performance

LFWD opened at $1.45 on Tuesday. The stock has a market capitalization of $15.41 million, a P/E ratio of -0.58 and a beta of 1.73. ReWalk Robotics has a 52-week low of $1.25 and a 52-week high of $6.00. The company’s 50-day simple moving average is $1.74 and its two-hundred day simple moving average is $2.22.

ReWalk Robotics (NASDAQ:LFWD) last issued its quarterly earnings results on Friday, March 7th. The company reported ($1.73) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($1.53). ReWalk Robotics had a negative return on equity of 43.02% and a negative net margin of 77.21%. The company had revenue of $7.55 million during the quarter, compared to analysts’ expectations of $7.30 million. Research analysts forecast that ReWalk Robotics will post -1.78 EPS for the current fiscal year.

Insider Buying and Selling at ReWalk Robotics

In other news, major shareholder Global Fund Lp Lind II sold 381,676 shares of the firm’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $3.36, for a total value of $1,282,431.36. Following the sale, the insider now directly owns 1,049,430 shares in the company, valued at approximately $3,526,084.80. This trade represents a 26.67 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 2.50% of the company’s stock.

About ReWalk Robotics

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke.